S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
RDGL · Vivos Inc
OTC MARKETS - Real Time Price • USD
$0.05
-0.00
(-3.14%)
● Overnight
DAY'S RANGE
$0.05
$0.04
$0.05
52-WEEK RANGE
$0.05
$0.04
$0.12
What's happening
- RDGL is down 3.14% today, trading at $0.05. — Live quote
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RDGL
-32.80%
vs S&P 500
-45.58%
1-YEAR RETURN
RDGL
-42.41%
vs S&P 500
-56.97%
6-MONTH RETURN
RDGL
-33.86%
3-MONTH RETURN
RDGL
-12.04%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2023-10-26 (Q3 2023)
$0.00
Est. $—
Valuation Measures & Ratios
Enterprise Value4$20.5M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)230.90
Price / Book710.97
EV4 / Revenue207.33
EV4 / EBITDA7.61
Profit Margin-3633.54%
Operating Margin-3707.76%
Return on Equity (ROE8)-154.94%
Return on Assets (ROA9)-144.14%
Avg Volume (3M)1,348,610
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short33,174
Change from Prior Settlement+219.26%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-15. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 142.7% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-08; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -3633.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is -42.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RDGL
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.4K | $36.1K | $1.9K | $15.0K | $26.7K | $5.0K | $13.5K | $4.5K |
| Gross profit | -$1.7K | -$8.0K | -$12.8K | -$34.8K | -$9.1K | $1.1K | $2.7K | -$1.5K |
| Operating income | -$654.5K | -$545.5K | -$531.0K | -$674.8K | -$863.5K | -$843.1K | -$522.3K | -$577.1K |
| Net income | -$830.2K | -$1.2M | -$507.3K | -$645.5K | -$834.7K | -$825.3K | -$503.5K | -$558.5K |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating margin | -$1.8K | -$1.5K | -$28.3K | -$4.5K | -$3.2K | -$16.9K | -$3.9K | -$12.8K |
| Net margin | -$2.3K | -$3.3K | -$27.0K | -$4.3K | -$3.1K | -$16.5K | -$3.7K | -$12.4K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $2.9M | $3.0M | $1.9M | $2.3M | $2.8M | $3.3M | $2.2M | $1.2M |
| Total liabilities | $124.0K | $253.2K | $206.7K | $112.7K | $96.5K | $115.4K | $86.2K | $48.8K |
| Stockholders' equity | $2.8M | $2.7M | $1.7M | $2.2M | $2.7M | $3.2M | $2.1M | $1.2M |
| Total current assets | $2.4M | $2.6M | $1.7M | $2.3M | $2.8M | $3.3M | $2.2M | $1.2M |
| Total current liabilities | $50.0K | $171.7K | $117.9K | $112.7K | $96.5K | $115.4K | $86.2K | $48.8K |
| Cash & equivalents | — | — | — | — | — | $3.3M | $2.2M | $1.2M |
| Accounts receivable | $15.7K | $7.7K | $22.3K | $4.7K | $13.3K | $8.7K | $10.3K | $5.0K |
| Inventory | $56.4K | $56.9K | $57.3K | $62.7K | $63.0K | $21.2K | — | — |
| Property, plant & equipment | $338.2K | $244.1K | $102.8K | — | — | — | — | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $3.0K | $3.0K | $3.0K | — | — | — | — | — |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $494.2K | $482.8K | $455.5K | $454.7K | $453.8K | $453.4K | $440.9K | $417.6K |
| Retained earnings | -$90.4M | -$89.6M | -$88.4M | -$87.3M | -$86.8M | -$86.2M | -$85.4M | -$84.3M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$739.6K | -$429.9K | -$539.6K | -$458.5K | -$604.5K | -$455.2K | -$470.9K | -$506.3K |
| Investing cash flow | -$94.5K | -$151.2K | -$103.2K | — | — | — | — | — |
| Financing cash flow | $644.4K | $1.5M | -$845 | $0 | $0 | $1.5M | $1.5M | $0 |
| Free cash flow | -$834.1K | -$581.1K | -$642.7K | — | — | — | — | — |
| Capital expenditures | $94.5K | $151.2K | $103.2K | — | — | — | — | — |
| Share-based compensation | — | — | — | — | — | — | — | — |
| Change in accounts receivable | $8.0K | -$14.7K | $17.6K | -$8.6K | $4.6K | -$1.6K | $5.3K | -$8.5K |
| Change in inventory | -$436 | -$394 | -$5.5K | -$227 | $41.8K | $21.2K | — | — |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $68.4K | $28.0K | $19.5K | $36.5K | $14.9K |
| Gross profit | -$59.8K | -$3.0K | -$6.0K | $7.7K | $2.9K |
| Operating income | -$3.2M | -$2.6M | -$2.8M | -$2.5M | -$2.5M |
| Net income | -$3.1M | -$2.9M | -$2.9M | -$2.5M | -$2.5M |
| EPS (diluted) | $-0.01 | $-0.01 | $-0.01 | $-0.01 | — |
| EPS (basic) | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
| Operating margin | -$4.6K | -$9.3K | -$14.3K | -$6.9K | -$16.8K |
| Net margin | -$4.5K | -$10.4K | -$14.8K | -$6.8K | -$17.0K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $1.9M | $2.2M | $1.6M | $1.7M | $1.6M |
| Total liabilities | $206.7K | $86.2K | $245.0K | $81.7K | $166.9K |
| Stockholders' equity | $1.7M | $2.1M | $1.4M | $1.7M | $1.5M |
| Total current assets | $1.7M | $2.2M | $1.6M | $1.7M | $1.6M |
| Total current liabilities | $117.9K | $86.2K | $245.0K | $81.7K | $166.9K |
| Cash & equivalents | — | $2.2M | $1.6M | $1.7M | $1.6M |
| Accounts receivable | $22.3K | $10.3K | $7.0K | $11.0K | — |
| Inventory | $57.3K | — | — | — | — |
| Property, plant & equipment | $102.8K | — | — | — | — |
| Intangible assets | — | — | — | — | $14.0K |
| Other non-current assets | $3.0K | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | — | — | — | — | — |
| Common stock & paid-in capital | $455.5K | $440.9K | $387.9K | $362.5K | $343.5K |
| Retained earnings | -$88.4M | -$85.4M | -$82.5M | -$79.6M | -$77.1M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$2.1M | -$1.7M | -$1.3M | -$1.1M | -$963.8K |
| Investing cash flow | -$103.2K | — | — | — | — |
| Financing cash flow | $1.5M | $2.3M | $1.2M | $1.2M | $1.7M |
| Free cash flow | -$2.2M | — | — | — | — |
| Capital expenditures | $103.2K | — | — | — | — |
| Share-based compensation | — | — | — | — | $1.6M |
| Change in accounts receivable | $12.0K | $3.3K | -$4.0K | $11.0K | — |
| Change in inventory | $57.3K | — | — | — | — |
| Change in accounts payable | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RDGL as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2022-11-17 to 2026-09-30
Recent transactions
- Insiders have net bought 927,550 shares over the last 182 days, across 10 purchases and 0 sales.
- Most recent: Korenko Michael K (CEO) — Open market purchase of 200,000 shares on 2026-09-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)927,550 sh(10 txns)
Sales (open market)0 sh(0 txns)
Net Shares+927,550
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Korenko Michael K | CEO | Open market purchase | 2026-09-30 | 200,000 |
| Weeks Brad Allan | President | Open market purchase | 2026-09-16 | 25,550 |
| POLLACK MICHAEL H | INTERIM CFO | Open market sale | 2023-03-24 | 16,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Korenko Michael K | CEO | Open market purchase | 200,000 | $0.50 |
| 2026-09-16 | Weeks Brad Allan | President | Open market purchase | 25,550 | $0.05 |
| 2026-08-10 | Weeks Brad Allan | President | Open market purchase | 50,000 | $0.05 |
| 2026-08-10 | Korenko Michael K | CEO AND PRESIDENT | Open market purchase | 150,000 | $0.05 |
| 2026-07-22 | Weeks Brad Allan | President | Open market purchase | 32,000 | $0.05 |
| 2026-07-21 | Weeks Brad Allan | President | Open market purchase | 60,000 | $0.05 |
| 2026-07-15 | Korenko Michael K | CEO AND PRESIDENT | Open market purchase | 200,000 | $0.06 |
| 2026-07-10 | Weeks Brad Allan | President | Open market purchase | 12,000 | $0.08 |
| 2026-07-09 | Weeks Brad Allan | President | Open market purchase | 48,000 | $0.08 |
| 2026-05-11 | Korenko Michael K | CEO AND PRESIDENT | Open market purchase | 150,000 | $0.06 |
| 2025-12-31 | Korenko Michael K | CEO AND PRESIDENT | Open market purchase | 200,000 | $0.06 |
| 2025-12-02 | Korenko Michael K | CEO AND PRESIDENT | Open market purchase | 100,000 | $0.07 |
| 2025-11-20 | Korenko Michael K | CEO AND PRESIDENT | Open market purchase | 100,000 | $0.06 |
| 2025-08-14 | Korenko Michael K | CEO AND PRESIDENT | Open market purchase | 100,000 | $0.08 |
| 2024-10-28 | Korenko Michael K | CEO AND PRESIDENT | Open market purchase | 50,000 | $0.14 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:35 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-08 | 4 | 2026-10-07 | View on SEC.gov → |
| 2026-10-08 | 8-K | 2026-10-07 | View on SEC.gov → |
| 2026-10-05 | 8-K | 2026-09-28 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-10 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-10 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-07-22 | 4 | 2026-07-21 | View on SEC.gov → |
| 2026-07-15 | 4 | 2026-07-15 | View on SEC.gov → |
| 2026-07-10 | 4 | 2026-07-09 | View on SEC.gov → |
| 2026-05-14 | 10-Q | 2026-03-31 | View on SEC.gov → |
Recent news
Headlines about RDGL (Vivos Inc). Links open the publisher — we don’t host full articles.
-
Vivos Therapeutics Regains Nasdaq Stockholders’ Equity Compliance After SOD Deal
Minichart · 2026-10-21 -
Vivos Therapeutics confirms Nasdaq compliance with $2.5M stockholders’ equity after SOD transaction
TradingView · 2026-10-21 -
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
Yahoo · 2026-10-21 -
SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
Yahoo · 2026-10-20 -
Vivos Therapeutics strikes $12 million stock deal for SOD Sciences stake
Indian Pharma Post · 2026-10-20 -
Vivos Therapeutics acquires stake in SOD Sciences By Investing.com
Investing.com Nigeria · 2026-10-20 -
Vivos Therapeutics Buys 11% of SOD Sciences, Gains 50% Stake in Diagnostic Test
Yahoo Finance · 2026-10-19 -
Vivos Therapeutics Acquires Stake in SOD Sciences and Half Interest in Pseudohypoxia Early-Warning Test
Quiver Quantitative · 2026-10-19
No headlines in this category right now — try “All”.